tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Meiser BM and Reichart B New trends in clinical immunosuppression. 1994 Transplant. Proc. pmid:7527954
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Ohtsuka S et al. Hamster-to-rat xenotransplantation of whole pancreas by FK 506 combined with splenectomy. 1994 Transplant. Proc. pmid:7513473
Hu RH et al. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. 2000 Transplant. Proc. pmid:11119894
Tzakis AG et al. Two-year experience with FK 506 in pediatric patients. 1993 Transplant. Proc. pmid:7679822
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. 1994 Transplant. Proc. pmid:7513476
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Jain A et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. 1998 Transplant. Proc. pmid:9636567
Matevossian E et al. Liver transplantation in the rat: single-center experience with technique, long-term survival, and functional and histologic findings. 2009 Jul-Aug Transplant. Proc. pmid:19715990
Videla CO Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy. 2009 Jul-Aug Transplant. Proc. pmid:19715995
Melo MJ et al. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study. 2015 Transplant. Proc. pmid:26036484
Viganó J et al. Incidence of graft rejection in small bowel transplanted pigs after immunosuppression withdrawal. 2006 Jul-Aug Transplant. Proc. pmid:16908291
Hossain MA et al. Effect of the immunosuppressants FK506 and D-allose on allogenic orthotopic liver transplantation in rats. 2000 Transplant. Proc. pmid:11120048
Sekido H et al. Successful conversion from cyclosporine to tacrolimus for immunosuppression. 2000 Transplant. Proc. pmid:11120096
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Kliem V et al. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation. 1999 Transplant. Proc. pmid:10576041
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Yilmaz A et al. Severe angioedema caused by banana allergy under tacrolimus immunosuppression. 2005 Transplant. Proc. pmid:16387091
Lai WJ et al. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? 2004 Transplant. Proc. pmid:15518744
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Perrella A et al. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. 2010 Transplant. Proc. pmid:20534267
Colak H et al. Relationship of Interleukin-10 and Transforming Growth Factor-β Levels With Short-Term Graft Function After Kidney Transplantation. 2015 Transplant. Proc. pmid:25964218
Peddi VR et al. Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9636626
Chen JS et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. 2009 Transplant. Proc. pmid:19545678
Cabello M et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. 2010 Transplant. Proc. pmid:20970603
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Li D et al. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. 2006 Transplant. Proc. pmid:17112846
Villamil F et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. 2006 Transplant. Proc. pmid:17112875
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Tullius SG et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. 2003 Transplant. Proc. pmid:14529854
Manu MA et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. 1999 Transplant. Proc. pmid:10578313
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Ushigome H et al. Two cases of tacrolimus-induced alopecia following kidney transplantation. 1999 Transplant. Proc. pmid:10578326
Woo J et al. Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. 1991 Transplant. Proc. pmid:1721319
Petan JA et al. Physiochemical properties of generic formulations of tacrolimus in Mexico. 2008 Transplant. Proc. pmid:18589125
Abecassis MM et al. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis. 2008 Transplant. Proc. pmid:18589126
Ito Y et al. Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection. 2002 Transplant. Proc. pmid:12176430
Shibutani S et al. FK 506 abrogates induction of regulatory cells after intratracheal delivery of alloantigen. 2002 Transplant. Proc. pmid:12176432
Ping X et al. Antigen sampling on the Peyer's patches in a murine small bowel transplantation model. 2010 Transplant. Proc. pmid:21094860
Marin M et al. Factors influencing the onset of diabetes mellitus after kidney transplantation: a single French center experience. 2005 Transplant. Proc. pmid:15919484
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Kumano K et al. Role of endothelin in FK 506-induced renal hypoperfusion in rats. 1995 Transplant. Proc. pmid:7533423
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Tanabe K et al. Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. 2002 Transplant. Proc. pmid:12176493
Ramirez CB et al. Early steroid withdrawal after liver transplantation. 1998 Transplant. Proc. pmid:9838406
Liu Y et al. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function. 2018 Transplant. Proc. pmid:30316359
Shapiro R Tacrolimus (FK-506) in kidney transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123077
Borda B et al. Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia. 2011 Transplant. Proc. pmid:21620104
Reggiani P et al. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation. 1996 Transplant. Proc. pmid:8907965
Jiang H et al. FK 506 and deoxyspergualin: additive immunosuppressive effect on rat cardiac allograft rejection in vivo and mitogen-stimulated human lymphocyte responses in vitro. 1994 Transplant. Proc. pmid:7520631
Wada Y et al. Expression of the transcriptional factor egr-1/BTEB2 in cardiac xenograft vascular remodeling. 2000 Transplant. Proc. pmid:10936371
Takayama K et al. Nonmuscle myosin heavy chain and nuclear factor-kappa B expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936372
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
Moons P et al. Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen. 2002 Transplant. Proc. pmid:12176538
Beaunoyer M et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. 2002 Transplant. Proc. pmid:12176540
Boots JM et al. Risk of adrenal insufficiency with steroid maintenance therapy in renal transplantation. 2002 Transplant. Proc. pmid:12176541
Navia MA Rational design of new immunosuppressive drugs. 1999 Feb-Mar Transplant. Proc. pmid:10083489
McAlister VC et al. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. 1999 Feb-Mar Transplant. Proc. pmid:10083495
Lee S et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. 2010 Transplant. Proc. pmid:20430174
Basadonna GP et al. Pancreas after kidney transplantation: HLA mismatch does not preclude success. 1997 Feb-Mar Transplant. Proc. pmid:9123470
Kato Y et al. Epidermal growth factor enhances the intestinal adaptation of small bowel allografts in the postoperative period. 2000 Transplant. Proc. pmid:10995935
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Yamanaka K et al. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. 2016 Transplant. Proc. pmid:27234735
Rigotti P et al. Antilymphocyte induction is no longer necessary in simultaneous pancreas and kidney transplantation. 2002 Transplant. Proc. pmid:12176623
Akbas SH et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. 2006 Transplant. Proc. pmid:16797284
Franke GH et al. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation. 2006 Transplant. Proc. pmid:16797285
Salazar A et al. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. 2001 Feb-Mar Transplant. Proc. pmid:11267181
Ziedina I et al. Reactivation of BK Virus in the Early Period After Kidney Transplantation. 2009 Transplant. Proc. pmid:19328975
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Burrows L et al. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. 1998 Transplant. Proc. pmid:9723378
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
Wang CH et al. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan. 2004 Transplant. Proc. pmid:15561256
Heffron TG et al. Daclizumab induction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267408
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
Rong G et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. 2010 Transplant. Proc. pmid:21094796
Zhang J et al. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients. 2010 Transplant. Proc. pmid:21094797
Barak S et al. Alveolar bone height in patients after liver transplantation. 2000 Transplant. Proc. pmid:10856558
Gotsman I et al. Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1. 2000 Transplant. Proc. pmid:10856569
Wong YT et al. Audit of diabetes in a renal transplant population. 2005 Transplant. Proc. pmid:16298573
Shapiro R The development of tacrolimus in renal transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750356
Blume C et al. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750357
Morris-Stiff G et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. 1998 Transplant. Proc. pmid:9636506
Busque S et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. 1998 Transplant. Proc. pmid:9636507